Virtus Health (ASX:VRT) share price shrugs off latest acquisition hurdle

The Virtus share price was unfazed by today's seemingly unfortunate news.

The Virtus Health Ltd (ASX: VRT) share price spent most of today in the green despite its planned acquisition being faced with a new challenge.

The company is waiting to complete its acquisition of Adora Fertility and 3 day hospitals, together known as the Adora Businesses. Currently, Healius Ltd (ASX: HLS) owns the Adora Businesses.

However, today Virtus announced the Australian Competition and Consumer Commission (ACCC) is planning to stop the acquisition from being finalised.

Despite the apparent bad news, Virtus performed quite well on the ASX today.

As of Wednesday's close, the Virtus share price is $5.47, 0.37% higher than Tuesday's closing price.

For context, the S&P/ASX 200 Index (ASX: XJO) fell 0.07% today.

Let's take a closer look at the new hurdle facing the healthcare company specialising in fertility treatments and day hospital services.

a man in a suit holds up a hand and a stop sign at a roadblock positioned over a bitumen road .

Image source: Getty Images

Virtus unfazed by ACCC roadblock

The Virtus share price gained today despite announcing seemingly unfortunate news.

The company has had its plans to acquire Adora Fertility and 3 day hospitals halted by the ACCC.

According to Virtus, the watchdog intends to seek an interim order from the Federal Court to prevent the acquisition's completion despite the ACCC's public review not being finalised.

However, Virtus is still planning to complete the acquisition. It said it will defend any proceedings.

The company also noted it has kept the ACCC in the loop throughout the acquisition process.

Virtus stated it has "constructively engaged" with the watchdog since it announced it would conduct a public review process of the acquisition

Virtus first announced its plans to acquire Adora Fertility and the 3 day hospitals back in August. It agreed to pay $45 million for the businesses. The funds were to come from a now-completed $35 million capital raise and existing cash reserves.

Virtus share price snapshot

Right now, the Virtus share price is around 3% higher than it was at the start of 2021. It is also 23% higher than it was this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Virtus Health Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL unveils exclusive Alentis deal to advance rare disease treatments

CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

CSL vs Pro Medicus: Which ASX healthcare share is better?

Both CSL and Pro Medicus have faced recent challenges but have enviable long-term track records. Here's which one I'd buy…

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This ASX biotech could rise almost 50%, Morgans says

Turning science into contracts could unlock value for this company.

Read more »

Doctor with stethoscope using a tablet in a hospital.
Healthcare Shares

Telix Pharmaceuticals wins FDA Fast Track for BiPASS prostate cancer imaging

Telix Pharmaceuticals shares are in the spotlight after the FDA granted Fast Track for its BiPASS pre-biopsy prostate cancer imaging…

Read more »

Three scientists looking at a laptop in a lab.
Healthcare Shares

What would it take for CSL shares to return to $250?

The shares have already recovered strongly, so I wanted to see whether $250 is realistic.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Is the ResMed share price a cheap buy?

I look at what the next few years of earnings growth could mean for today’s valuation.

Read more »